Pharmaceutical Technology on MSN
How biotech executives are confronting the funding and regulatory shifts
Amidst regulatory turmoil and a funding resurgence, companies provide insights on how they are navigating the changing ...
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min This week's roundup of life ...
Welcome to another edition of Core Biotech!I started this portfolio with the objective of proving that Long-Term investing in the biotech sector is a worthwhile endeavor.New buys and sells are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results